story of the week
Outcomes of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as Initial Therapy in Patients With HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3
Ann. Oncol 2024 May 08;[EPub Ahead of Print], MP Goetz, M Toi, J Huober, J Sohn, O Trédan, IH Park, M Campone, SC Chen, LM Manso, S Paluch-Shimon, OC Freedman, J O'Shaughnessy, X Pivot, SM Tolaney, S Hurvitz, A Llombart-Cussac, V André, A Saha, G van Hal, A Shahir, H Iwata, SRD JohnstonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.